Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00325780
Other study ID # NK-104-307
Secondary ID 2005-001112-41
Status Completed
Phase Phase 3
First received February 10, 2006
Last updated January 25, 2010
Start date July 2006
Est. completion date November 2007

Study information

Verified date January 2010
Source Kowa Research Europe
Contact n/a
Is FDA regulated No
Health authority United Kingdom: National Health ServiceSpain: Spanish Agency of MedicinesIndia: Indian Council of Medical Research
Study type Interventional

Clinical Trial Summary

This study is a long-term follow-up protocol for patients who participated in study NK-104-3.01EU or study NK-104-3.02EU.


Description:

Patients from the NK-104-3.01EU and NK-104-3.02EU studies will continue to receive either pitavastatin or the comparator statin for 1 year.


Recruitment information / eligibility

Status Completed
Enrollment 1355
Est. completion date November 2007
Est. primary completion date November 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Patients have completed 12 weeks of treatment in Study NK-104-301 (NCT00249249) or NK-104-302 (NCT00309777)

- Patients who have not developed any treatment emergent and, in the opinion of the investigator, related adverse event (AE) of clinical significance where the investigator is uncomfortable with continuing the patient on therapy with pitavastatin.

- Patients who have been following a fat and cholesterol restrictive diet.

Exclusion Criteria:

- Any conditions which may cause secondary dyslipidemia should be reassessed at the beginning of the follow-up study.

- Uncontrolled diabetes mellitus should be reassessed at the beginning of the follow-up study.

- Abnormal pancreatic, liver, or renal function

- Abnormal serum ALAT/SGPT/ALT, ASAT/SGOT/AST, or creatine kinase (CK) above the pre-specified level

- Significant heart disease

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Pitavastatin
Pitavastatin 4 mg once daily

Locations

Country Name City State
Denmark Copenhagen University Hospital Copenhagen
Denmark Medical Center Copenhagen
Denmark Y Forskning, Bispebjerg Hospital Copenhagen Nv
Denmark Frederiks Hospital, Kardiologisk Frederiksberg
Denmark Kolesterollaboratoriet Hellerup
Denmark CCBR A/S Vejle
Finland Geri-Med Oy Helsinki
Finland Kaisaniemen Laakariasema Helsinki
Finland Keravan Laakarikeskus Helsinki
Finland SOK-Tyoterveyshuolto Tampere
Finland TYKS University Hospital Turku
Germany Kardiologische Gemeinschaftspraxis Prof. Reifart Bad Soden/Taunus
Germany Praxis Dr. Boenninghoff Beckum
Germany Klinische Forschung Berlin Mitte Berlin
Germany Gemeinschaftspraxis am Bahnhof Berlin-Spandau
Germany Pharmakologisches Studienzentum Chemnitz Chemnitz
Germany GWT-TUK mbH, Zentrum fur Klinische Studien Dresden
Germany Internistische Diabetische Schwerpunktpraxis Dr. Frankfurt Am Main
Germany Gemeinschaftspraxis Dr. Krause, Th. Menke Goch
Germany Klinische Forschung Hamburg Hamburg
Germany Innere Medizin I/Medizinische Klinik Heidelberg
Germany Gemeinschaftspraxis H. Holz Dr. Med, K. W. Klingl Lampertheim
Germany ZET-Studien GmbH Leipzig Leipzig
Germany Internistische Gemeinschaftspraxis Mainz
Germany Praxis Dr. Wachter Mannheim
Germany Gemeinschaftspraxis Melcherstaette Melcherstaette
Germany Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler Messkirch
Germany Praxisgemeinschaft im Kleinen Biergrund Offenbach/M
Germany Gemeinschaftspraxis Drs. Mockesch Weinheim
Germany Intermed Institud fur Klinische Forschung und Arzn Wiesbaden
Germany Gemeinschaftspraxis Dr. Emden, Frank Drewes Worpswede
India Care Hospital Andhra Pradesh
India School of Diabetology, Nizam Institute of Medical Sciences Andhra Pradesh
India Bhagwan Mahaveer Jain Heart Centre Bangalore
India Sri Ramachandra Medical College Hospital Chennai
India Heart Care Clinic Gujarat
India Apollo Hospitals Hyderabad
India CARE Group of Hospitals Hyderabad
India St. John's Medical College Hospital Karnataka
India Bathia Hospital Maharashtra
India King Edward Medical College & Hospital Maharashtra
India Lokmanya Hospital Maharashtra
India LTMMC & General Hospital Maharashtra
India Ruby Hall Clinic Maharashtra
India Sir J. J. Group of Hospitals Maharashtra
India PD Hinduja Hospital Mumbai
India Sir Gagaram Hospital New Delhi
India Apollo Hospital Tamil Nadu
India Department of Cardiology Tamil Nadu
Israel Department of Internal Medicine, Soroka Medical Center Beersheva
Israel Department of Internal Medicine A, Rambal Medical Center Haifa
Israel Department of Internal Medicine, Wolfson Medical Center Holon
Israel Center for Research, Hadassah University Hospital Jerusalem Ein Kerem
Israel Meir Hospital Kfar Saba
Israel Department of Medicine, Hadassah Medical Center Mount Scopus Jerusalem
Israel Department of Internal Medicine, Rivka Sieff Medical Center Safed
Israel Institute of Metabolic Diseases Tel Aviv
Israel Institute of Lipid & Atherosclerosis Research Tel Hashomer
Italy Dipartimento di Medicina Clinica e Biotecnologia Applicata Bologna
Italy Centro di Ricerca Clinica Chieti
Italy Gerontologia e Geriatria - Universita degli Studi Ferrara
Italy Dipartimento di Medicina Interna DIMI Genova
Italy Universita di Modena e Reggio Emilia, Policlinico Modena
Italy Dipartimento di Medicina Clinica e Sperimentale Napoli
Italy Medicina Clinica e delle Patologie Emergenti Palermo
Italy Dipartimento di Medicina Interna e Scienze Biomediche Parma
Italy U.O. Malattie Metaboliche e Diabetologia Treviglio
Italy Azienda Ospedaliero-Universitaria Trieste
Netherlands Andromed Breda Breda
Netherlands Middellaan 5 Breda
Netherlands Andromed Eindhoven Eindhoven
Netherlands Bomanshof 8 Eindhoven
Netherlands Andromed Noord Groningen
Netherlands Damsterdiep 9 Groningen
Netherlands Vasculair Onderzoek Centrum Hoorn Hoorn
Netherlands Andromed Leiden Leiden
Netherlands Doezastraat 1 Leiden
Netherlands Andromed Nijmegen Nijmegen
Netherlands Kamerlingh Onnesstraat 16-18 Nijmegen
Netherlands Andromed Rotterdam Rotterdam
Netherlands Mathenesserlaan 247 Rotterdam
Netherlands Albert Schweitzer Ziekenhuis Sliedrecht
Netherlands Andromed Oost Velp
Netherlands Reigerstraat 30 Velp
Netherlands Rivierenland Tiel Wp Tiel
Netherlands Andromed Zoetermeer Zoetermeer
Netherlands Parkdreef 142 Zoetermeer
Norway Nyomen Legekontor Kongsberg
Norway Radhuset Spesialistsenter Oslo
Norway Rikshospitalet - University Hospital Oslo
Norway Skedsmo Medisinske Senter A.S. Skedsmokorset
Poland Podlaski Osrodek Kardiologii Bialystok
Poland NZOZ GCP Dobra Praktyka Lekaska Gruziadz
Poland NZOZ Terapia Optima Katowice
Poland NZOZ Esculap, Przychodnia Lekary Rodzinnych Losice
Poland NZOZ Centrum, Poradnia Kardiologiczna Siedlce
Poland Spec. Gab. Lek. Internistyczno-Kardiologicznly Tarnow
Poland Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego Tychy
Poland Instytut Zywnosci i Zywienia Warszawa
Poland Lecznica PROSEN SMO Warszawa
Poland Szpital Wolski,im. Dr A. Gostynskiej Warszawa
Russian Federation Kemerovo Cardiology Dispensary Kemerovo
Russian Federation Central Clinical Hospital 1 of RZD Moscow
Russian Federation City Clinical Hospital 23 Moscow
Russian Federation City Clinical Hospital 64 Moscow
Russian Federation Federal State Institution Out-Patient Clinic 3 of Russian Federation of President’s Management Moscow
Russian Federation Moscow City Clinical Hospital 68 Moscow
Russian Federation Moscow Regional Research Clinic Institute n.a.M.F.Vladimirov, Department of Therapy Moscow
Russian Federation State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Department of Internal Diseases and Rheumatology based at City Clinica Moscow
Russian Federation State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Hospital Therapy Department # 1 based at City Clinical Hospital # 40 Moscow
Russian Federation State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Hospital Therapy Department #1 based at City Clinical Hospital # 52 Moscow
Russian Federation State Educational Institution of Higher Professional Education “Russian State Medical University Federal Agency of Health Care and Social Development�, Department of Polyclinic Therapy based at Diagnostic Center # 1 Moscow
Russian Federation State Educational Institution of Higher Professional Education “Russian State Medical University Federal Agency of Health Care and Social Development�, Department of Therapy based at City Hospital # 4 Moscow
Russian Federation State Educational Institution of Higher Professional Education “Russian State Medical University of Federal Agency of Health Care and Social Development�, Department of Hospital Therapy #1 based at City Clinical Hospital #15, Cardiology Depar Moscow
Russian Federation State Institution “Research Institute of Physical and Chemical Medicine� of Federal Agency of Health Care and Social Development, Laboratory of Clinical Cardiology based at Bauman City Hospital # 29 Moscow
Russian Federation State Institution “Russian Cardiology Research Complex� of Federal Agency of Health Care and Social Development, Myasnikov Clinical Cardiology Institute, Department of Hemodialysis and Plasmapheresis Moscow
Russian Federation State Research Center for Preventive Medicine Moscow
Russian Federation Novosibirsk Reg. Clinical Cardiology Dispensary Novosibirsk
Russian Federation Central Medical Unit 122, St. Pb Saint Petersburg
Russian Federation Clinical Hospital of Russian Academy of Sciences Saint Petersburg
Russian Federation Consulting and Diagnostic Center 85 Saint Petersburg
Russian Federation Krestovsky Island Medical Institute Saint Petersburg
Russian Federation Pokrovskaya City Hospital Saint Petersburg
Russian Federation St. Petersburg State Medical Institution “Out-patient Clinic # 109� Saint Petersburg
Russian Federation St.Petersburg State Medical Institution “Pokrovskaya City Hospital�, Cardiology Department #2 Saint Petersburg
Russian Federation State Educational Institution of Higher Professional Education, “Saint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Development�, Chair and Department of Faculty Therapy Saint Petersburg
Russian Federation State Educational Institution of Higher Professional Education, “Saint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Development�, Institute of Cardiovascular Diseases Saint Petersburg
Spain Hospital de San Vicente Alicante
Spain Hospital Santa Creu I Sant Pau Barcelona
Spain Hospital Universitario de Bellvitge Barcelona
Spain Hospital Vall d'Hebron Barcelona
Spain Hospital Universitario Reina Sofia Cordoba
Spain Centro de Especialidades Pedro Gonzalez Bueno Madrid
Spain Fundacion Jimenez Diaz Madrid
Spain Hospital Clinico San Carlos Madrid
Spain Hospital Ramon y Cajal Madrid
Spain Centro de Salud de Ventanielles Oviedo
Spain Hospital Clinico S. Juan de Alicante San Juan Alicante
Spain Hospital Marques de Valdecilla Santander
Spain Hospital Clinico Universitario de Santiago Santiago de Compostela
Spain Hospital Virgen del Roci-o Sevilla
Spain Hospital de Sagunto Valencia
Spain Hospital Dr. Peset Valencia
Spain Hospital Clinic i Provincial Villaroel Barcelona
Spain Hospital Clinico Lozano Blesa Zaragoza
Spain Hospital Miguel Servet Zaragoza
Sweden Angelholms Sjukhus, Medicinkliniken Angelhom
Sweden Sahlgrenska University Hospital, Intermedicin Gothenburg
Sweden Hjartmottagningen Helsingborg
Sweden Lakarcentrum Nyponet Karineholm
Sweden Medicinkliniken Ludvika
Sweden Huslakaren i Sandviken Sandviken
Sweden Narsjukhuset Sandviken, Kardiologlab, Medicin Sandviken
Sweden Hjart & Karlcenter Sodertalje
Sweden Karolinska Universitetssjukhuset Stockholm
Sweden Hjarthuset AB Varberg
United Kingdom Oldfield Surgery Bath
United Kingdom St James's Surgery Bath
United Kingdom St Michael's Partnership Bath
United Kingdom The Pulteney Practice Bath
United Kingdom Birmingham Clinical Research Centre Birmingham
United Kingdom Stonehill Medical Center Bolton
United Kingdom Avondale Surgery Chesterfield
United Kingdom Chorley Clinical Research Centre Chorley
United Kingdom Saltash Health Center Cornwall
United Kingdom Gomersal Lane Surgery Dronfield
United Kingdom Townhead Research Irvine
United Kingdom Crosby Clinical Research Centre Liverpool
United Kingdom The Symons Medical Center Maidenhead
United Kingdom Manchester Clinical Research Centre Manchester
United Kingdom Greenwood Medical Center Nottingham
United Kingdom Knowle House Surgery Plymouth
United Kingdom Reading Clinical Research Centre Reading
United Kingdom Elm Lane Surgery Sheffield
United Kingdom The Burngreave Surgery Sheffield
United Kingdom Brook Lane Surgery Southampton
United Kingdom St Helier Hospital Surrey
United Kingdom Box Surgery Wiltshire
United Kingdom Bradford Road Medical Center Wiltshire
United Kingdom Eastleigh Surgery Wiltshire
United Kingdom Lovemead Group Practice Wiltshire
United Kingdom Rowden Medical Partnership Wiltshire
United Kingdom St Chad's Surgery Wiltshire
United Kingdom The Health Centre Wiltshire
United Kingdom The Porch Surgery Wiltshire
United Kingdom The Burns Medical Practice Yorkshire

Sponsors (1)

Lead Sponsor Collaborator
Kowa Research Europe

Countries where clinical trial is conducted

Denmark,  Finland,  Germany,  India,  Israel,  Italy,  Netherlands,  Norway,  Poland,  Russian Federation,  Spain,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Baseline to 52 Weeks No
Secondary Change From Baseline in Total Cholesterol Baseline to 52 weeks No
See also
  Status Clinical Trial Phase
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Recruiting NCT03947866 - Ezetimibe-Rosuvastatin Evaluation Study
Completed NCT01709513 - Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) Phase 3
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed NCT02550288 - A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383) Phase 3
Completed NCT03929198 - Translation of Pritikin Program to the Community N/A
Completed NCT04485793 - Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia N/A
Completed NCT02341924 - Validating the "Foods for Health" Portfolio of Functional Food Products N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Completed NCT01941836 - Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients Phase 2
Completed NCT01934608 - The Effect of Synching Prescription Refills on Adherence N/A
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01678521 - Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients N/A
Completed NCT01670734 - Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects Phase 1
Completed NCT01370603 - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1) Phase 3
Completed NCT01370590 - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1) Phase 3
Completed NCT01478789 - Efficacy of Plant Sterol-Fortified Dairy Product on Plasma Lipid and Plant Sterol Concentrations in Humans N/A
Completed NCT01446679 - Special Drug Use-Results Survey of Lipitor Tablets N/A
Completed NCT01768403 - Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia N/A